Effects of Prescription Omega-3-Acid Ethyl Esters on Non-High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin

Bays, Harold E.; McKenney, James; Maki, Kevin C.; Doyle, Ralph T.; Carter, Roderick N.; Stein, Evan
February 2010
Mayo Clinic Proceedings;Feb2010, Vol. 85 Issue 2, p122
Academic Journal
OBJECTIVE: To evaluate the effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol (HDL-C) levels In atorvastatin-treated patients with elevated non-HDL-C and triglyceride levels. PATIENTS AND METHODS: This study, conducted between February 15, 2007, and October 22, 2007, randomIzed patients with elevated non-HDL-C (>160 mg/dL) and trIglycerIde (⩾250 mg/dL and ⩽599 mg/dL) levels to double-blInd treatment with prescription omega-3-acid ethyl esters, 4 g/d, or placebo for 16 weeks. Patients also received escalating dosages of open-label atorvastatin (weeks 0-8,10 mg/d; weeks 9.1.2,20 mg/d; weeks 13-16,40 mg/d). RESULTS: Prescription omega-3-acid ethyl esters plus atorvastatin, 10, 20, and 40 mg/d, reduced median non-HDL-C levels by 40.2% vs 33.7% (P<001), 46.9% vs 39.0% (P<.001), and 50.4% vs 46.3% (P<.001) compared with placebo plus the same doses of atorvastatin at the end of 8, 12, and 16 weeks, respectively. Prescription omega-3-acid ethyl esters plus atorvastatin also reduced median total cholesterol, triglyceride, and very low-density lipoprotein cholesterol levels and increased HDL-C levels to a significantly greater extent than placebo plus atorvastatin. Percent changes from baseline low-density lipoprotein-cholesterol, apollpoprotein A-I, and apolipoprotein B levels were not significantly different between groups at the end of the study. CONCLUSION: Prescription omega-3-acid ethyl esters plus atorvastatin produced significant improvements In non-HDL-C and other lipid parameters in patients with elevated non-HDL-C and triglyceride levels.


Related Articles

  • Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men. WONG, Annette T. Y.; CHAN, Dick C.; OOI, Esther M. M.; NG, Theodore W. K.; WATTS, Gerald F.; BARRETT, . Hugh R. // Clinical Science;2013, Vol. 125 Issue 1, p45 

    Dysregulated VLDL-TAG (very-low-density lipoprotein triacylglycerol) metabolism in obesity may account for hypertriacylglycerolaemia and increased cardiovascular disease. ω-3 FAEEs (omega-3 fatty acid ethyl esters) decrease plasma TAG and VLDL concentrations, but the mechanisms are not fully...

  • Agent for reducing very high triglycerides.  // Corporate Meetings & Incentives;Mar2006 Las Vegas Supplement, Vol. 25, p14 

    The article provides information on the lipid-regulating agent Omacor from Reliant, which is indicated as an adjunct to diet to reduce very triglyceride levels in adults. The drug contains the ethyl esters of omega-3 fatty acids. Since treatment with Omacor may cause elevations in low density...

  • Randomized Study of the Safety and Efficacy of Fish Oil (Omega-3 Fatty Acid) Supplementation with Dietary and Exercise Counseling for the Treatment of Antiretroviral Therapy--Associated Hypertriglyceridemia. Wohl, David A.; Lien, Hsiao-Chuan; Busby, Marjorie; Cunningham, Catherine; MacIntosh, Beth; Napravnik, Sonia; Danan, Elisheva; Donovan, Kimberly; Hossenipour, Mina; Simpson, Jr., Ross J. // Clinical Infectious Diseases;11/15/2005, Vol. 41 Issue 10, p1498 

    Background. Omega-3 fatty acids (fish oils) reduce fasting serum triglyceride levels and cardiovascular disease risk in individuals without HIV infection. Whether omega-3 fatty acid supplementation can reduce hypertrigly-ceridemia associated with antiretroviral therapy is not known. Methods. We...

  • Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Neubronner, J; Schuchardt, J P; Kressel, G; Merkel, M; von Schacky, C; Hahn, A // European Journal of Clinical Nutrition;Feb2011, Vol. 65 Issue 2, p247 

    Background:There is a debate currently about whether different chemical forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are absorbed in an identical way. The objective of this study was to investigate the response of the omega-3 index, the percentage of EPA+DHA in red blood...

  • TEST QUESTIONS.  // Drug Topics;Jan2015, Vol. 159 Issue 1, p48 

    The article presents questions and answers related to healthcare topics including the over-the-counter products recommended to promote cardiovascular health in healthy patients, omega-3 fatty acids present in fatty fish, and products that are potent in lowering triglyceride levels.

  • Limited Impact of 2 g/day Omega-3 Fatty Acid Ethyl Esters (Omacor) on Plasma Lipids and Inflammatory Markers in Patients Awaiting Carotid Endarterectom. Yusof, Hayati M.; Cawood, Abbie L.; Ding, Ren; Williams, Jennifer A.; Napper, Frances L.; Shearman, Clifford P.; Grimble, Robert F.; Payne, Simon P.K.; Calder, Philip C. // Marine Drugs;Sep2013, Vol. 11 Issue 9, p3569 

    The objective of this study was to determine the effects of prescription omega-3 (n-3) fatty acid ethyl esters (Omacor®) on blood pressure, plasma lipids, and inflammatory marker concentrations in patients awaiting carotid endarterectomy. Patients awaiting carotid endarterectomy (n = 121)...

  • Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet.  // Lipids in Health & Disease;2012, Vol. 11 Issue 1, p70 

    The article presents a study which aimed at investigating short term effects of triglyceride (TG), ethyl ester (EE), free fatty acid (FFA) and phospholipid (PL) forms of omega-3 fatty acid (FA) on lipid metabolism in mice. It notes that serum and hepatic lipid concentrations were analyzed, as...

  • First Rx omega-3 product offers purity, proven benefit. Belden, Heidi // Drug Topics;11/7/2005, Vol. 149 Issue 21, p14 

    This article reports on the launch of Omacor, an omega-3-acid ethyl esters, of Reliant Pharmaceuticals Inc. and approved by the U.S. Food and Drug Administration in Liberty Corner, New Jersey. The new formulation is indicated as an adjunct to diet for adults with very high blood levels of...

  • The benefits of flax.  // Consumer Reports on Health;Apr2009, Vol. 21 Issue 4, p10 

    The article discusses the benefits of flax products and how to include it in one's diet. Flax products are available in supplements, oil and the seed itself which contain omega-3 fatty acids like fish oil. These substances protect the heart by thinning the blood and lowering levels of LDL...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics